While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...
Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...
Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...
Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results ...
The Phase 3 "BASIS" trial data, showcased at the American Society of Hematology (ASH) annual meeting, showed significant promise. For patients with inhibitors—a subgroup historically difficult to ...
More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...
Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...
The group will discus and vote on whether to recommend Pfizer booster shots. The Food and Drug Administration's independent advisory committee will convene in open session Friday to review the latest ...
NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
The US Food and Drug Administration is taking a closer look at RSV shots for infants as Health and Human Services Secretary ...
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback